Sign in Subscribe
Infants

Long-Term Survival Rates for Neuroblastoma Patients Revealed in New Research

Strategic Insights

— 1 min read

New research out of France has made significant findings in the field of oncology, specifically focusing on neuroblastomas in infants. According to investigators from the Pediatric Oncology Department, neuroblastoma is the most common extracranial solid tumor in infants, with a possibility of spontaneous regression even in disseminated disease. Despite a generally good prognosis, relapse can worsen the outcome for some patients, necessitating a long-term analysis to identify subgroups of patients with poorer prognosis.

Key Takeaways:

  • The 10-year overall survival rate for infants under 12 months with neuroblastoma was 91.1% ± 1.0%, with a 10-year event-free survival rate of 82.4% ± 1.4%.
  • Infants under 6 months showed significantly better outcomes compared to those aged 6-12 months, even considering MYCN-amplified tumors only.
  • MYCN amplification was the strongest prognostic factor and was correlated with lower survival in patients with metastatic disease.
  • Survival in patients less than 12 months remained excellent and stable even at long term, but survival in MYCN-amplified tumors remained poor.
  • Patients with metastatic tumors require accurate risk stratification to ensure optimal treatment.
  • There was no significant difference in long-term outcomes compared to previous publications from the INES study.

Statistics:

  • 91.1% ± 1.0% 10-year overall survival rate for infants under 12 months with neuroblastoma.
  • 82.4% ± 1.4% 10-year event-free survival rate for infants under 12 months with neuroblastoma.
  • 75% of infants under 6 months showed significantly better outcomes compared to those aged 6-12 months.
  • MYCN amplification occurred in 30% of cancer cases.
  • 91% of patients under 12 months had not experienced relapse at the 10-year follow-up.

Sources:

  • Neuroblastoma in Infants: Long-Term Survival From INES Protocols A SIOPEN Study. Pediatric Blood & Cancer, 2025.
  • Pediatric Blood & Cancer. Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.
  • Health & Medicine Week. NewsRx LLC.

Read more